A Randomized, Dbl-Blind, Placebo-Controlled, Parallel-Grp, Multictr, Ph 3 Study-Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

Administered By

Awarded By

Contributors

Start/End

  • December 20, 2013 - December 19, 2016